TO TREAT HER2-POSITIVE CANCERSHER2-positive cancers represent up to 30% of all cases of breast, gastric, pancreatic, colorectal and other forms of cancer, Abpro said in a statement.“ABP-102/CT-P72 represents a breakthrough in the bispecific antibody space, addressing the long-standing toxicity barriers that have hindered the development of HER2-targeted T cell engagers,” said Celltrion Senior Vice President and Head of the New Drug Division Lee Soo Young.“The strong preclinical efficacy and safety data support its potential to redefine treatment options for patients with HER2-positive cancers.”Celltrion and Abpro plan to start clinical trials of ABP-102/CT-P72 in the first half of 2026.
The two companies joined forces in 2022 to develop bispecific antibody therapies for HER2-positive cold tumors.“Based on those results, we aim to accelerate the development of multivalent antibody therapies while targeting the next-generation anticancer drug market,” said a Celltrion official in a statement.
ABP-102/CT-P72, a tetravalent bispecific HER2 x CD3 T-cell engager developed by Celltrion and Abpro, is engineered to selectively target HER2-overexpressing tumors while reducing the risk of on-target, off-tumor toxicity in normal tissues, the two companies said.
The story "Celltrion unveils cancer medicine to expand new drug pipelines" has 326 words across 17 sentences, which will take approximately 2 - 3 minutes for the average person to read.
Which news outlet covered this story?
The story "Celltrion unveils cancer medicine to expand new drug pipelines" was covered 10 hours ago by Korea Economic Daily, a news publisher based in South Korea.
How trustworthy is 'Korea Economic Daily' news outlet?
Korea Economic Daily is a fully independent (privately-owned) news outlet established in 1964 that covers mostly economy news.
The outlet is headquartered in South Korea and publishes an average of 6 news stories per day.
It's most recent story was published 7 hours ago.
What do people currently think of this news story?
The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.
How do I report this news for inaccuracy?
You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
